GENOVA,Inc. Q3 FY2025 earnings call

• Company Mission and Core Business

  • Operates under the mission of "Connecting people and healthcare to build a healthy society", with two core business segments.
  • Medical Platform Business centers on Medical DOC, a consumer-facing medical information media that reduces information asymmetry between patients and healthcare providers, and helps clinics attract patients to grow their revenue.
  • Smart Clinic Business provides clinic automation solutions to reduce operational costs and improve patient experience.

• Overall Financial Results

  • Consolidated revenue reached 7.61 billion yen, up 25% YoY; operating profit was 1.62 billion yen, up 11% YoY; net profit attributable to parent company shareholders was 1.08 billion yen, up 15% YoY.
  • Third quarter operating profit progress came in slightly below plan due to increased selling, general and administrative expenses (SG&A) and cost of goods sold (COGS).

• Business and Operational Updates

  • Medical Platform: The new Clinic Visit Report service (launched Q4 FY2024) gained traction with new customers, driving a record-high number of contracts for the quarter. Average selling price for other services remained high due to growth in sales of high-value keywords. Reservation and inquiry functions were added to Medical DOC this fiscal year, and video content expansion via partnerships is underway to boost brand awareness. Growing public interest in health information is increasing Medical DOC's audience and media value, supporting a self-reinforcing value-up cycle driven by network effects.
  • Smart Clinic: Follow-up to the prior launch of NOMOCa-AI chat, NOMOCa-AI call was launched in November 2024 to automate clinic call handling. A sales reorganization for hardware services caused a temporary decline in sales volume this quarter, but management expects the revised management structure to strengthen branch and agency partnerships. The NOMOCa-AI call launch did not contribute to Q3 revenue due to delayed sales expansion and client demand for trial periods; trial adoption started in Q4, with revenue contribution expected as early as March 2025 and full contribution from April 2025 onward. New specialized internal teams were launched: a dedicated sales hiring team and a new agency partner promotion department.

• Capital and Shareholder Strategy

  • A secondary share offering was completed to increase the floating share ratio, to meet the Prime Market listing maintenance requirement of 10 billion yen floating market capitalization, improve stock liquidity, and expand the shareholder base, aligned with the long-term goal of reaching 100 billion yen market capitalization.
  • A share repurchase program of up to 500,000 shares or 0.9 billion yen was launched concurrently to offset supply pressure from the offering and strengthen shareholder returns. As of the call, 275,000 shares had been repurchased for a total consideration of 370.204 million yen, and the floating share ratio rose to the mid-50% range, creating a buffer for future listing compliance.

1. Medical Platform Business: Revenue of 4.79 billion yen (19% YoY growth), gross profit of 4.34 billion yen, contributing 63% of total consolidated revenue. It grew YoY and was flat compared to the previous quarter, with monthly page views hitting 17.59 million for its core medical media Medical DOC. 2. Smart Clinic Business: Combined revenue from hardware and software services of 2.39 billion yen (45% YoY growth), gross profit of 1.1 billion yen, contributing 31% of total consolidated revenue. It saw slight YoY revenue growth but a sequential decline from the previous quarter, with cumulative installed units of automated checkout and self-checkout devices exceeding 2,300 units.

No explicit full-year guidance revision was provided in the transcript. Management's forward-looking statements are:

• Medical DOC will continue to expand content and functionality to grow its user base, and is currently preparing to launch elder care information coverage to address growing demand for aged care.
• GENOVA will continue expanding low-price and subscription-based services across both business segments to accelerate customer base growth.
• NOMOCa-AI call is expected to begin contributing to revenue as early as March 2025, with full revenue contribution starting from April 2025, and management expects the product to drive future growth given high client satisfaction during trials.
• Management will continue pursuing business growth to increase share price and strengthen shareholder returns, aligned with the long-term target of reaching 100 billion yen market capitalization.

• Operating cost pressures: SG&A increased due to higher rent and relocation costs from Q2 office expansion, free upgrades for new banknote compatibility, strengthened inside sales driving higher promotional costs, and R&D spending for the new Medical DOC reservation function, partially expensed in Q3. COGS for the Medical Platform business also rose due to increased video content production.
  • Smart Clinic growth headwinds: Sequential decline in hardware unit sales and consecutive departures of software service sales staff led to slower growth and a YoY decline in operating profit for the segment, with the overall consolidated operating profit coming in slightly below plan.
  • Delayed commercialization: The newly launched NOMOCa-AI call failed to contribute to Q3 revenue due to delayed sales expansion and client preference for trial adoption.

No question and answer section was included in the provided transcript.